English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduCommonly referred to as “magic mushrooms,” psilocybin is a promising alternative treatment for people with medication-resistant depression and anxiety.
Tag: psilocybin
In psychedelic therapy, clinician-patient bond may matter most
Drug effects have dominated the national conversation about psychedelics for medical treatment, but a new study suggests that when it comes to reducing depression with psychedelic-assisted therapy, what matters most is a strong relationship between the therapist and study participant.
Psilocybin – a promising therapy for treatment-resistant depression?
A growing body of evidence suggests that psychedelic drugs may be useful in treating various mental health conditions. However, many challenges remain in defining their clinical benefits and overcoming the complex regulatory obstacles to their use.
Reduced frequency & intensity of migraine attacks after single dose of psilocybin
Psilocybin – the active ingredient in psychedelic mushrooms – shows promise for the transitional treatment of episodic migraines in early clinical trials, according to a review from Yale School of Medicine’s Emmanuelle Schindler, M.D., Ph.D. In the first and only…
How hallucinogenic substance in psilocybin mushrooms works on the molecular level
Psilocybin is a hallucinogenic compound found in about 200 mushroom species, including the liberty cap (Psilocybe semilanceata).
Psychiatrists disagree with U.S. policy on psychoactive drugs
A new national survey reveals considerable differences between psychiatrists’ perceptions about the safety and therapeutic value of certain psychoactive drugs and how those same drugs are categorized under U.S. policy.
Predicting who may do best with psychedelic-assisted therapy
A new research review identifies personality traits that have been associated with positive and negative experiences on psychedelics being tested for therapeutic purposes in previous studies, information that could help predict how future clinical trial participants will respond to the drugs.
One psychedelic experience may lessen trauma of racial injustice
A single positive experience on a psychedelic drug may help reduce stress, depression and anxiety symptoms in Black, Indigenous and people of color whose encounters with racism have had lasting harm, a new study suggests.
Psychedelic Treatment with Psilocybin Relieves Major Depression, Study Shows
In a small study of adults with major depression, Johns Hopkins Medicine researchers report that two doses of the psychedelic substance psilocybin, given with supportive psychotherapy, produced rapid and large reductions in depressive symptoms, with most participants showing improvement and half of study participants achieving remission through the four-week follow-up.
A Scientific First: How Psychedelics Bind to Key Brain Cell Receptor
For the first time, scientists at UNC-Chapel Hill and Stanford solved the high-resolution structure of psychedelic drugs bound to the 5-HT2A serotonin receptor, a major step toward understanding how the drugs cause such wild effects and how they might be better used to treat psychiatric conditions.
Research News Tip Sheet: Story Ideas from Johns Hopkins Medicine
During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our “COVID-19 Tip Sheet: Story Ideas from Johns Hopkins” every Tuesday throughout the duration of the outbreak.
RESEARCH NEWS TIP SHEET: STORY IDEAS FROM JOHNS HOPKINS
The June 4, 2020, issue of the weekly Johns Hopkins Medicine research newsletter on topics NOT related to COVID19. Stories this week: study shows pollutant may be more hazardous than previously thought; psilocybin tampers the brain’s ego center; and getting urban youth to wear bike helmets.
The Psychedelic Science of Pain
The Arthur C. Clarke Center for Human Imagination at UC San Diego organized the collaborative Psychedelics and Health Research Initiative, which explores the potential for psychedelics to address chronic pain conditions.